P/E ratio for BioXcel Therapeutics (BTAI)
P/E ratio as of June 2024 (TTM): -0.1660
According to BioXcel Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.165963. At the end of 2022 the company had a P/E ratio of -3.63.
P/E ratio history for BioXcel Therapeutics from 2018 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -3.63 | -27.06% |
| 2021 | -4.98 | -59.12% |
| 2020 | -12.2 | 68.54% |
| 2019 | -7.23 | 149.21% |
| 2018 | -2.90 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.09 | 1,762.91% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.